On-Demand Webinar Discusses Promising Developments in Single-Cell Multi-Omic Cancer Research
The Scientist recently hosted a webinar as part of its LabTools webinar series which highlighted how IsoPlexis’ multi-omic energy state application generates unique mechanistic insights into therapeutic resistance in cancer. Dr. James Heath, President and Professor at the Institute for Systems Biology and a founder and board member of IsoPlexis, was the featured speaker, discussing the future of functional multi-omic research in oncology.
Extracting Metabolic and Phosphoproteomic Information from Single Cells Generates Insights into Cancer Biology
In this webinar, Dr. Heath highlighted why single-cell metabolomics and phosphoproteomics are critical for studying the development of therapeutic resistance in cancer. Dr. Heath explained how cancer cells are “chameleons” due to their ability to change their function so that they no longer respond to targeted treatment. This resistance can emerge without changes to the genome. Tumor growth and adaptation is associated with elevated metabolic activity, measured by glucose uptake, hyperactivated signaling, measured by phosphoprotein levels, and increased cell proliferation. Thus, it is critical to look at both the metabolome and phosphoproteome to generate the most predictive insights.
Dr. Heath went on to discuss these topics:
- The strengths and limitations of current methods and technologies for examining cancer cell resistance
- Addressing these limitations with multi-omic technology, such as that from IsoPlexis, that can simultaneously measure metabolites and phosphoproteins on the single cell level
- The Nature Communications study he led, which examined how cancer cells transition between drug-responsive and drug-resistant cell states by analyzing cells treated with BRAF inhibitor over a period of five days
IsoPlexis’ Single-Cell Multi-Omic Energy State Application Solves Core Research Challenges
Following Dr. Heath’s presentation, IsoPlexis delved further into how multi-omic technology resolves challenges in cancer research. A startling 60% of labs working in proteomics say they lack meaningful data that correlates with outcome, (there is a similar low correlation of 0.4 between transcriptomics data and true cellular function) and 62% of labs say that lack of time is a barrier to achieving their goals. IsoPlexis addresses these core issues facing researchers by capturing proteins and metabolites reflecting in vivo biology. IsoPlexis’ highly multiplexed Single-Cell Metabolome solution captures 15+ phosphoproteins and metabolites per panel with unique proteomic barcoding. This solution works by capturing 500-1500 single cells in microchambers, where the cells are lysed. Striped antibody barcodes within the microchambers use capture antibodies to highly quantify the proteins and metabolites from each single cell. In addition to providing the high correlation with in vivo function that researchers are missing, IsoPlexis’ platform saves valuable time with walk-away automation of incubation, staining, wash cycle, data analysis, and more.
Watch the full webinar now to learn more.